GlycoPEGylated recombinant factor IX for hemophilia B in context
Elena Santagostino, Maria Elisa Mancuso Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca’ Granda Foundation, Maggiore Hospital Policlinic, Milan, Italy Abstract: Decisions over hemophilia treatment selection and switching involve balancing many clinical and patient-related...
Saved in:
Main Authors: | Santagostino E (Author), Mancuso ME (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014) -
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
by: Mark T. Reding, et al.
Published: (2024) -
A new recombinant factor VIII: from genetics to clinical use
by: Santagostino E
Published: (2014) -
Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
by: Pasca S, et al.
Published: (2022) -
"Diagnosis of Hemophilia B Carriers, Using Taq I and Xmn I Polymorphisms of the FactorIX Gene in Iranian Individuals"
by: P Ghandil, et al.
Published: (2003)